Regulatory guides

On February 18, 2026, FDA announced that one adequate, well-controlled trial plus confirmatory evidence is now the default bar for marketing authorization, instead of two trials. A companion Plausible Mechanism framework goes further for rare disease programs. Here is what sponsors need to plan for, and what it means for your data.